A retrospective single-center study on the effectiveness and tolerability of emicizumab in patients with hemophilia a with and without inhibitors
Emicizumab prophylaxis effectively reduces ABRs and enhances joint health in severe HA patients, irrespective of inhibitor presence, providing a convenient, well-tolerated alternative to FVIII therapy.
Authors
- Amr Mahmoud Amin
- Shafqat Ahmad (ORCID: https://orcid.org/0000-0002-3873-7943)
- Suhail Muzaffar (ORCID: https://orcid.org/0000-0002-8064-9488)
- Maliha Rohi
- Sheikh Fahad
Institutions
- Shri Maharaja Hari Singh Hospital (IN)
- Government Medical College and Hospital (IN)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1080/17474086.2025.2471862
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77